SiccaNova Therapeuticsis a startup developing novel low-molecular therapeutics targeting dry mouth (xerostomia) and dry eye conditions.
SiccaNova Therapeutics has raised $7.9M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
SiccaNova Therapeutics's investors include JIC Venture Growth Investments, MPower Partners, Tohoku University Venture Partners, Joyo Capital Partners, 77 Partners.
SiccaNova Therapeutics is headquartered in Tsukuba, Japan.
SiccaNova Therapeuticsis a startup developing novel low-molecular therapeutics targeting dry mouth (xerostomia) and dry eye conditions.
SiccaNova Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SiccaNova Therapeutics — Funding & Investors." VCBacked, September 3, 2026, https://www.vcbacked.co/company/siccanova-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). SiccaNova Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/siccanova-therapeutics
{{cite web |title=SiccaNova Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/siccanova-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated